2 weeks Ago By ABMN Staff
Texas Permanent School Fund Corp cut its holdings in shares of Alkermes plc ( NASDAQ:ALKS – Free Report ) by 14.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 124,906 shares of the company’s stock after selling 21,146 shares during the quarter.
Texas Permanent School Fund Corp owned about 0.07% of Alkermes worth $3,010,000 as of its most recent filing with the Securities and Exchange Commission. Several other large investors have also recently added to or reduced their stakes in ALKS.
EFG Asset Management North America Corp. raised its holdings in shares of Alkermes by 0.5% in the 2nd quarter.
EFG Asset Management North America Corp. now owns 75,864 shares of the company’s stock worth $1,828,000 after purchasing an additional 359 shares during the period. United Services Automobile Association raised its holdings in shares of Alkermes by 3.
1% in the 2nd quarter. United Services Automobile Association now owns 13,208 shares of the company’s stock worth $318,000 after purchasing an additional 400 shares during the period. Signaturefd LLC raised its holdings in shares of Alkermes by 51.
2% in the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock worth $34,000 after purchasing an additional 480 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Alkermes by 1.
0% in the 4th quarter. Fisher Asset Management LLC now owns 59,942 shares of the company’s stock worth $1,663,000 after purchasing an additional 572 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Alkermes by 44.
4% in the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock worth $55,000 after purchasing an additional 703 shares during the period. 95.
21% of the stock is currently owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth A number of equities analysts have recently commented on ALKS shares. StockNews.
com upgraded Alkermes from a “hold” rating to a “buy” rating in a report on Sunday, July 28th. TD Cowen began coverage on Alkermes in a research note on Monday, June 17th. They issued a “buy” rating and a $34.
00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $48.00 target price on shares of Alkermes in a research note on Thursday, July 25th.
Robert W. Baird increased their target price on Alkermes from $37.00 to $38.
00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Finally, HC Wainwright increased their target price on Alkermes from $35.00 to $37.
00 and gave the company a “neutral” rating in a research note on Thursday, July 25th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.
com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $36.70. Alkermes Price Performance Shares of NASDAQ ALKS opened at $27.
66 on Monday. Alkermes plc has a fifty-two week low of $22.01 and a fifty-two week high of $32.
88. The business has a 50 day moving average price of $26.66 and a two-hundred day moving average price of $25.
85. The company has a quick ratio of 2.61, a current ratio of 2.
99 and a debt-to-equity ratio of 0.22. The firm has a market cap of $4.
68 billion, a PE ratio of 10.93, a price-to-earnings-growth ratio of 0.56 and a beta of 0.
46. Alkermes ( NASDAQ:ALKS – Get Free Report ) last issued its earnings results on Wednesday, July 24th. The company reported $0.
70 EPS for the quarter, hitting the consensus estimate of $0.70. The company had revenue of $399.
13 million during the quarter, compared to analyst estimates of $393.30 million. Alkermes had a return on equity of 23.
20% and a net margin of 19.15%. The business’s revenue was down 35.
4% on a year-over-year basis. During the same quarter last year, the firm earned $0.38 EPS.
Sell-side analysts expect that Alkermes plc will post 2.36 earnings per share for the current fiscal year. Alkermes Profile ( Free Report ) Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Featured Articles Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter .
.
